Construction of ajmalicine and sanguinarine de novo biosynthetic pathways using stable integration sites in yeast

Biotechnol Bioeng. 2022 May;119(5):1314-1326. doi: 10.1002/bit.28040. Epub 2022 Jan 31.

Abstract

Yeast cell factories have been increasingly employed for producing plant-derived natural products. Unfortunately, the stability of plant natural product biosynthetic pathway genes, particularly when driven by the same sets of promoters and terminators, remains one of the biggest concerns for synthetic biology. Here we profile genomic loci flanked by essential genes as stable integration sites in a genome-wide manner, for stable maintenance of multigene biosynthetic pathways in yeast. We demonstrate the application of our yeast integration platform in the construction of sanguinarine (24 expression cassettes) and ajmalicine (29 expression cassettes) de novo biosynthetic pathways for the first time. Moreover, we establish stable yeast cell factories that can produce 119.2 mg L-1 heteroyohimbine alkaloids (containing 61.4 mg L-1 ajmalicine) in shake flasks, representing the highest titer of monoterpene indole alkaloids (MIAs) ever reported and promising the complete biosynthesis of other high-value MIAs (such as vinblastine) for biotechnological applications.

Keywords: CRISPR/Cas9; ajmalicine; alkaloids; multiplex genome integration; plant natural products; sanguinarine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzophenanthridines
  • Biosynthetic Pathways* / genetics
  • Indole Alkaloids / metabolism
  • Isoquinolines
  • Saccharomyces cerevisiae / genetics
  • Saccharomyces cerevisiae / metabolism
  • Secologanin Tryptamine Alkaloids* / metabolism

Substances

  • Benzophenanthridines
  • Indole Alkaloids
  • Isoquinolines
  • Secologanin Tryptamine Alkaloids
  • raubasine
  • sanguinarine